Shared on10 Oct 25Fair value Increased 2.09%
Analysts have raised their price target for CVS Health, increasing it by nearly $2 to approximately $84 per share. They cite improved earnings visibility and strengthening fundamentals in the healthcare sector as key reasons for the change.
Shared on04 Sep 25Fair value Increased 0.61%
Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.
Shared on30 Apr 25Fair value Decreased 0.78%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Increased 4.83%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 0.36%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.30%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.39%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 8.86%
AnalystConsensusTarget has increased revenue growth from 4.7% to 5.2% and increased future PE multiple from 12.6x to 13.9x.